Back to All Combinations

MSS (Immunotherapy Emerging)

Prognosis
85.00% Prevalence Level 3 Immunotherapy
Actionable Target
FDA-approved targeted therapies or strong clinical trial evidence available
Genes Involved
MMR proficient
Treatment Implications

EMERGING: Botensilimab + Balstilimab showing breakthrough activity (ORR 24%, DCR 73% in refractory MSS mCRC). FDA breakthrough therapy designation. Phase 3 trials ongoing. Standard options: Chemotherapy, TAS-102 + Bevacizumab (SUNLIGHT), Fruquintinib (FRESCO-2).

Recommended Treatments
Botensilimab + Balstilimab (clinical trials)
TAS-102 + Bevacizumab
Fruquintinib
Regorafenib
Standard chemotherapy
Treatments to Avoid

No specific contraindications noted

Study References

Botensilimab Phase 1/2, SUNLIGHT (PMID: 37133585), FRESCO-2 (PMID: 37331369)

Key Statistics
85.00%
Prevalence in CRC
Yes
Targetable
Clinical Notes
MSS/pMMR tumors are traditionally resistant to checkpoint inhibitors. Botensilimab is Fc-enhanced anti-CTLA-4 with improved T-reg depletion. First IO showing meaningful activity in MSS CRC. SUNLIGHT established TAS-102 + Bevacizumab as third-line standard (OS 10.8mo).
Information

Category: Immunotherapy

Evidence Level: Level 3

Last Updated: Dec 21, 2025

Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.